Skip to main content
Premium Trial:

Request an Annual Quote

Ross Perot Gives MD Anderson $20M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ross Perot has donated $20 million to the University of Texas MD Anderson Cancer Center to develop new cancer therapies, the center announced yesterday.

The funds will be divided equally between MD Anderson's Institute for Personalized Cancer Therapy and a Center for Targeted Therapy.

IPCT leverages discoveries made by its researchers to determine specific genetic and molecular abnormalities in a patient's cancer so that appropriate therapies can be prescribed. CTT is one of seven centers in the Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer at MD Anderson and is focused on coordinating all stages of the new-drug discovery and development process in order to accelerate new and less toxic drugs to the clinic from the research lab.

According to John Mendelsohn, president of MD Anderson, the donation from Perot will accelerate research into genetic blueprints, the identification of biomarkers, the development of cancer drugs, and the testing of new drugs in clinical trials.

"These funds will enable our clinicians and researchers to advance the translation of science into new and improved cancer treatments," Mendelsohn said in a statement.

Perot, who ran for President in 1992 and 1996, is the founder of Electronic Data Systems and Perot Systems.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more